Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 909 (LINC00909)
- Target
- LINC00909
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA (asRNA), Intergenic lncRNA
01
Overview
Long intergenic non-protein coding RNA 909 (LINC00909, also known as ZNF407 antisense RNA 1 or ZNF407-AS1) is a cytoplasmic long non-coding RNA transcribed from the antisense strand of the ZNF407 gene locus. It does not code for a protein and instead acts primarily through post-transcriptional mechanisms, notably by destabilizing SMAD4 mRNA, leading to downregulation of SMAD4 and subsequent upregulation of pluripotency genes and activation of oncogenic signaling pathways (e.g., MAPK/JNK). LINC00909 is overexpressed in several cancers, including pancreatic ductal adenocarcinoma and glioma, where it promotes cancer stemness, tumor metastasis, and is associated with poor clinical outcomes. Its functional role as a regulator of mRNA stability and signaling makes it of interest as a biomarker and a potential (though not yet directly druggable) molecular target in cancer[1][2][4].
- Other names
- ZNF407 antisense RNA 1ZNF407-AS1LINC00909long intergenic non-protein coding RNA 909
02
Mechanism of action
Not applicable as a pharmacological target; as a lncRNA, impacts cell biology via regulation of mRNA stability, notably by decreasing SMAD4 stability, and modulating stemness and metastasis-related pathways
03
Biological functions
Regulation of gene expression (post-transcriptional regulation)Regulation of cancer stemnessModulation of mRNA stability (notably SMAD4 mRNA)Promotion of cell proliferationPromotion of metastasisRegulation of pluripotency factorsParticipation in signaling pathways (MAPK/JNK, NF-κB, JAK-STAT, P53)
04
Disease associations
Cancer (notably pancreatic ductal adenocarcinoma, glioma, hepatocellular carcinoma, bladder urothelial carcinoma)Cancer stem cell maintenanceChemoresistance in cancer
05
Safety considerations
Therapeutic targeting of lncRNAs poses challenges such as specificity, off-target effects, delivery, and unknown regulatory roles in normal tissue
06
Interacting drugs
No direct drugs identified; involvement in response to gemcitabine in pancreatic cancer cells is reported, but not as a direct target
07
Biomarkers
LINC00909 expression level is a biomarker for poor prognosis and potentially for patient selection in pancreatic ductal adenocarcinoma and other tumors
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 909 (LINC00909).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 909 (LINC00909).